Advertisement

Endocrine

pp 1–3 | Cite as

Antineoplastic activity of artemisinin in adrenocortical carcinoma

  • Luigi Lorini
  • Salvatore Grisanti
  • Roberta Ambrosini
  • Deborah Cosentini
  • Marta Laganà
  • Luigi Grazioli
  • Guido A. M. Tiberio
  • Sandra Sigala
  • Alfredo BerrutiEmail author
Research Letter
  • 24 Downloads

Artemisia annua is a medicinal plant that is used in China to treat various diseases for over two millenniums. Preclinical studies revealed that the compound has a cytotoxic activity against various types of cancer cells [1].

Data on anticancer activity of artemisinin in humans are limited, but case reports and small case series have shown encouraging results in patients affected by metastatic breast cancer, colorectal cancer, and uveal melanoma [2].

The main mechanism of artemisinin antineoplastic activity is not fully elucidated. This drug and relevant derivatives display a multitarget activity, as frequently observed in most natural products [3]. Indeed, artemisinin compounds could block the activation of intracellular pathways such as Wnt/β-catenin, BCR/ABL, or by inducing cell cycle arrest, alteration of DNA repair mechanisms and inducing death via apoptosis and nonapoptotic pathways.

Concerning the artemisinin safety profile, reported adverse effects, such as renal, hepatic, and...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was supported with the contribution of FIRM Foundation (Cremona, Italy).

Informed consent

Informed consent was obtained from the patient included in the study.

References

  1. 1.
    Y. Zhang, G. Xu, S. Zhang, D. Wang, P. Saravana Prabha, Z. Zuo, Antitumor research on artemisinin and its bioactive derivatives. Nat. Prod. Bioprospect. 8(4), 303–319 (2018)CrossRefGoogle Scholar
  2. 2.
    Z. Li, Q. Li, J. Wu, M. Wang, J. Yu, Artemisinin and its derivatives as a repurposing anticancer agent: what else do we need to do? Molecules 21(10), 1331 (2016)CrossRefGoogle Scholar
  3. 3.
    T. Efferth, E. Koch, Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Target 12(1), 122–132 (2011)CrossRefGoogle Scholar
  4. 4.
    L.A. Panossian, N.I. Garga, D. Pelletier, Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann. Neurol. 58(5), 812–813 (2005)CrossRefGoogle Scholar
  5. 5.
    L. Liu, L.F. Zuo, J.W. Guo, Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line. Oncol. Lett. 6(5), 1475–1481 (2013)CrossRefGoogle Scholar
  6. 6.
    J.-L. Zhang, Z. Wang, W. Hu, S.-S. Chen, X.-E. Lou, H.-J. Zhou, DHA regulates angiogenesis and improves the efficiency of CDDP for the treatment of lung carcinoma. Microvasc. Res. 87, 14–24 (2013)CrossRefGoogle Scholar
  7. 7.
    S.-J. Wang, Y. Gao, H. Chen, R. Kong, H.-C. Jiang, S.-H. Pan et al. Dihydroartemisinin inactivates NF-κB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett. 293(1), 99–108 (2010)CrossRefGoogle Scholar
  8. 8.
    T. Efferth, Cancer combination therapies with artemisinin-type drugs. Biochemical Pharmacol. 139, 56–70 (2017)CrossRefGoogle Scholar
  9. 9.
    R. Libé, I. Borget, C.L. Ronchi, B. Zaggia, M. Kroiss, T. Kerkhofs et al. Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann. Oncol. 26(10), 2119–2125 (2015)CrossRefGoogle Scholar
  10. 10.
    A. Berruti, R. Libè, M. Laganà, H. Ettaieb, M.A. Sukkari, J. Bertherat et al. Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. Eur. J. Endocrinol. 180(5), 311–320 (2019)CrossRefGoogle Scholar
  11. 11.
    M. Fassnacht, O.M. Dekkers, T. Else, E. Baudin, A. Berruti, R.R. de Krijger et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179(4), G1–G46 (2018)CrossRefGoogle Scholar
  12. 12.
    L. Ferrari, M. Claps, S. Grisanti, A. Berruti, Systemic therapy in locally advanced or metastatic adrenal cancers: a critical appraisal and clinical trial update. Eur. Urol. Focus. 1(3), 298–300 (2016)CrossRefGoogle Scholar
  13. 13.
    P. Sperone, A. Ferrero, F. Daffara, A. Priola, B. Zaggia, M. Volante et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr. Relat. Cancer 17(2), 445–453 (2010)CrossRefGoogle Scholar
  14. 14.
    J.E.K. Henning, T. Deutschbein, B. Altieri, S. Steinhauer, S. Kircher, S. Sbiera et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J. Clin. Endocrinol. Metab. 102(11), 4323–4332 (2017)CrossRefGoogle Scholar
  15. 15.
    M. Terzolo, F. Daffara, A. Ardito, B. Zaggia, V. Basile, L. Ferrari et al. Management of adrenal cancer: a 2013 update. J. Endocrinol. Investig. 37(3), 207–217 (2014)CrossRefGoogle Scholar
  16. 16.
    D. Cosentini, S. Grisanti, V.A. Dalla, M. Laganà, C. Fiorentini, P. Perotti et al. Immunotherapy failure in adrenocortical cancer: where next? Endocr. Connect. 7(12), E5–E8 (2018)Google Scholar
  17. 17.
    G. Assié, E. Letouzé, M. Fassnacht, A. Jouinot, W. Luscap, O. Barreau et al. Integrated genomic characterization of adrenocortical carcinoma. Nat. Genet. 46(6), 607–612 (2014)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Luigi Lorini
    • 1
  • Salvatore Grisanti
    • 1
  • Roberta Ambrosini
    • 2
  • Deborah Cosentini
    • 1
  • Marta Laganà
    • 1
  • Luigi Grazioli
    • 2
  • Guido A. M. Tiberio
    • 3
  • Sandra Sigala
    • 4
  • Alfredo Berruti
    • 1
    Email author
  1. 1.Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public HealthUniversity of Brescia. ASST Spedali CiviliBresciaItaly
  2. 2.Radiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public HealthUniversity of Brescia. ASST Spedali CiviliBresciaItaly
  3. 3.Surgical Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public HealthUniversity of Brescia. ASST Spedali Civili di BresciaBresciaItaly
  4. 4.Section of Pharmacology, Department of Molecular and Translational MedicineUniversity of BresciaBresciaItaly

Personalised recommendations